Headache is more frequent in patients treated with CTLA-4-inhibitor or combination therapy, while the predominant symptoms of PD-1/PD-L1-inhibitor induced hypophysitis are fatigue, anorexia and myalgias (99, 100). The gene discussed is CTLA4; the disease is hypophysitis.